Home / Business and Economy / Hologic Acquires Genomics Pioneer for Breast Cancer Fight
Hologic Acquires Genomics Pioneer for Breast Cancer Fight
20 Oct
Summary
- Hologic is acquiring Barcelona-based Reveal Genomics, a precision oncology company.
- Reveal Genomics' HER2DX test aids in optimizing HER2-positive breast cancer therapy.
- The acquisition aims to expand Hologic's diagnostic oncology solutions for women.
Hologic, a global leader in women's health, announced its definitive agreement to acquire Reveal Genomics. This Barcelona, Spain-based company specializes in precision oncology, developing advanced genomic diagnostic tests for personalized cancer treatment. Its HER2DX test is particularly noted for optimizing therapy for patients with HER2-positive breast cancer.
The acquisition represents a significant expansion of Hologic's diagnostic oncology solutions. Reveal Genomics' offerings are highly complementary to Hologic's existing portfolio, which includes the Breast Cancer Index test. This combined offering is expected to enhance treatment decision-making for a greater number of women diagnosed with breast cancer.
According to Vitor Rocha, CEO of Diagnostic Solutions at Hologic, Reveal Genomics' portfolio is a strong strategic complement. He stated that the acquisition demonstrates Hologic's commitment to innovation and expands its ability to inform breast cancer treatment decisions. Patricia Villagrasa-Gonzalez, CEO and co-founder of Reveal Genomics, expressed that joining Hologic will accelerate their mission to bring precision oncology closer to patients worldwide.
The completion of this acquisition is contingent upon Spanish regulatory approval and other customary closing conditions. This strategic move underscores Hologic's dedication to advancing women's health through innovative diagnostic technologies.
